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ABSTRACT
The hydrophilic desferrioxamine (DFO) and the lipophilic salicy- 
laldehyde isonicotinoyl hydrazone (SIH) are iron chelators 
which inhibit in vitro proliferation of Plasmodium falciparum  with 
similar potency (1C50 —20 juM in 24- to 48-h tests). The in vivo 
assessment of these drugs was performed on Swiss mice 
infected with Plasmodium vinckei petteri with novel modes of 
drug administration and release. The drugs were delivered 
postpatently either by multiple Lp. injections or by a single i.p, 
or s.c. insertion of a drug-containing polymeric device which 
released most of the drug within 7 days at apparently first-order 
rates. A regimen of three daily i.p injections of 5 mg DFO for 3 
consecutive days or a 70-mg dose of the drug given as an i.p. 
or s.c. polymer implant evoked similar delay and reduction in 
peak parasitemias and reduced mortality with no apparent 
signs of toxicity. Relatively faster, but otherwise similar results
were obtained with the less hydrophilic SIH. In combination, the 
two drugs apparently potentiated each other. The polymeric 
devices were particularly useful for treating Piasmodium  
berghei K173-infected C57BI mice, a suggested model of ce­
rebral malaria, in which classical methods of DFO delivery were 
ineffective. The insertion of a 140-mg DFO-containing device 
on day 6 postinfection (parasitemia led to a marked
reduction in parasite proliferation, appearance of neurological 
sequelae and mortality of mice. Our studies indicate that poly­
meric devices for slow drug release might be highly advanta­
geous for both hydrophilic and lipophilic drugs whose antima- 
larial efficacy might depend on the maintenance of sustained 
blood levels. The results obtained with slow-release devices 
have implications for malaria chemotherapy as well as for iron 
chelation therapy in iron overload conditions.
Resistance of Plasmodium falciparum to chloroquine, qui­
nine, sulfadoxine, pyrimethamine and mefloquine has cre­
ated an urgent need for new drugs which are effective against 
multidrug-resistant strains of malaria (Peters, 1990). Strat­
egies to overcome resistance have relied on the application of 
drugs of different chemical character and mode of action 
(Vennerstrom et aL> 1991), including iron-chelating agents 
(reviewed in Cabantchik et al., 1996; Gordeuk etal., 1994). At 
present the only iron-ehe latin g drug approved for human 
treatment is DFO, of which the parenteral administration 
demands hospitalization. Synthetic iron chelators which can 
be administered orally are not suitable for chemotherapy, 
either because of human toxicity or lack of antimalarial effi­
cacy (Mabeza et a i ,  1996). In general, various types of drugs
Received for publication August 13, 1996.
1 This work was supported in part by the National Institutes of Health, 
grant AI20342 (Z,I,C.) and by the Authority for Research and Development of 
the Hebrew University (J.G.). Plasm odium  vinckei petteri was obtained from 
Prof. I. Landau from Pasteur Institute, Pai'is.
that inhibit parasite growth in culture were found to be only 
partially effective in in vivo studies because of inadequate 
speed of action on parasite development, reversibility of in­
hibition or pharmacokinetic factors. DFO is a hydrophilic 
agent that permeates rather slowly into parasitized cells and 
only at advanced stages of parasite growth (Fritsch and Jung 
1986; Scott et al., 1990; Loyevsky et a l 1993). Therefore, the 
time window of action of such an agent is relatively limited 
and the antimalarial activity is slow to develop, even after 
continuous m vitro or in vivo exposure to the drug (Lytton et 
al., 1994; Cabantchik et a l ., 1996). The same has been ob­
served in DFO-treated malaria patients, most of whom had 
recrudescence 7 to 10 days after cessation of drug treatment 
(Bunnag et al., 1992; Gordeuk et a l 1993).
We have recently shown that the antimalarial potential of 
various iron chelators could be markedly improved by 1) 
increasing drug lipophilicity leading to increased access of 
drug to intracellular parasites and to faster speed of action 
(Loyevsky et a/., 1993; Lytton et a l 1994) and 2) incorpora-
ABBREVIATIONS: CM, cerebral malaria; DFO, desferrioxamine; DMSO, dimethyl sulfoxide; poly(FAD-SA), poly (dimer erucic acid-co-sebacic 
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tion of cleavable groups for augmenting intracellular drug 
retention and attaining more persistent cytotoxic effects (Ca- 
bantchik et a l 1996; Tsafack et al., 1996a). Although fast 
speed of action and persistent inhibition are conferred to 
drugs by apparently opposite chemical properties, they can 
be accomplished by use of permeant lipophilic prodrugs 
which produce intracellular impermeant hydrophilic drugs 
(Tsafack et al. , 1996a). However, a major drawback of li­
pophilic drugs is their poor water solubility, which might 
limit their in vivo application. An alternative and versatile 
means of drug administration to animals is based on poly­
mers into which lipophilic or hydrophilic drugs can be encap­
sulated and released in a controlled fashion (Chasin et al .,
1990). Those polymers whose degradation products are both 
nontoxic and can be completely eliminated from the circula­
tion are particularly useful because they serve both as a safe 
medium for drug administration and as a vehicle for slow 
drug delivery (Domb et a l . , 1993). A polymer implant of 
nondegradable properties has recently been used as a slow- 
release device for the antifolate pyrimethamine in rodent 
malaria (Vandamme and Heller, 1995)*
The two iron chelators chosen for this study, the hydro­
philic DFO and the lipophilic SIH, were previously shown to 
act synergistically on in vitro cultures of P. falciparum. 
(Tsafack et al. , 1996b). Tn this work they were assessed in two 
rodent models of malaria: Swiss mice infected with Plasmo­
dium vinckei petteri and the C57bl mice infected with Plas­
modium berghei, a suggested model of CM, In this CM model, 
the petechial hemorrhages that are characteristic of CM were 
attributed to sequestration of mononuclear white cells which 
interact with, and infiltrate across, the endothelium and 
postcapillary venules (Grau et al., 1986; Curfs et al., 1989; 
Eling and Sauer wein, 1995). However, the hallmark of CM in 
human malaria is parasite sequestration (MacPherson et al,, 
1985), a property which has also been described recently in a 
rodent model (Kaul et ah, 1994). The chelators were assessed 
as therapeutic agents via two modes of administration: by 
multiple i.p. injections and by s.c. or i.p. insertion of a single 
dose of drug (or combination of drugs) which was encapsu­
lated into biodegradable polymers. The latter were found to 
be convenient, safe and efficient vehicles for antimalarial 
drug delivery.
Materials and Methods
Iron Chelators
SIH was prepared as described elsewhere (Baker et ah, 1992) and 
DFO was purchased from Ciba Geigy (Basel, Switzerland) as Des- 
feraL
Animal Models of Malaria
Two plasmodial strains that cause malaria in mice were used: 1) P. 
vinckei petteri in Swiss mice (females, 35-45 g, 10-12 weeks old) and 
2) P. berghei K 173 in C57BI mice (same sex and age) which display 
neurological disorders. The mice were infected with plasmodia by i.p. 
injection of infected blood (diluted with saline) from donor animals in 
which parasites were maintained by weekly transfer of infected 
blood. The parasitemias and body temperatures were measured. A 
correlation was found between decrease in body tempei'ature (below 
30°C) within approximately 24 h before death in the second week and 
the presence of lesions in the brain as determined post mortem 
(Polder et ah, 1992; Eling and Sauerwein, 1995).
Parasite Development
Parasitemias were assessed by use of Gie ms a-stained blood 
smears.
Drug Delivery Systems
Devices contain ing DFO. We used matrices of a bioerodible 
polymer, poly(FAD-SA), that releases DFO in vitro for 7 days with 
first-order kinetics. The matrices were designed to obtain a similar 
in vitro release profiles for all screened drugs. The matrices used 
undergo in vivo degradation and elimination within G weeks after 
release of the drugs (Domb et ah, 1995). They were prepared first by 
melting the polymer on a hot plate at 70°C, removing it from the 
plate and mixing quickly with the drug powder (30-40% by weight), 
The mixture was then pressed between two metal plates to obtain a 
film of the appropriate thickness (2 mm) and the polymer was cut to 
obtain the desired dose. In vitro slow-release tests of the drugs were 
performed by placing the polymer tablet in 20 ml PBS (0.1 M, pH 7,4) 
and incubating it at 37°C. The solution, which was replaced daily, 
was used for drug determination by UV-visible absorption of the 
iron-hydroxamate complex (at 420 nm) after addition of excess FeCla, 
The polymer itself was estimated according to its dry weight.
Devices containing SIH. SIH (160 mg) was dissolved in 2.5 ml 
of DMSO and added to the polymer solution (114 mg polyethylene 
glycol 4000, 320 mg PSA and 22.8 mg Tween 80 in 8 ml chloroform). 
The mixture was stirred thoroughly, the solvents were evaporated 
with a rotavaporator and traces of DMSO were vaporized with high 
vacuum. Another 160 mg of PSA was added, the mixture was melted 
at 60~70°C for complete mixing and was allowed to stand overnight 
to form tablets of 97.5 mg (about 2 x 3 x 5  inm). Devices loaded with 
different amounts of SIH were produced similarly by use of propor­
tional amounts of the ingredients. SIH released from the polymer 
was monitored by placing each polymer sample in 20 ml PBS at 37°C
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Fig. 1. Cumulative release of DFO (upper) or SIH (lower) from polymers 
into salt solutions. The polymers [poly(FAD-SA)] contained 30 or 40% 
DFO or 30% SIH and the indicated amounts of the drugs.
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Fig. 2. Comparative efficacy of modes 
of DFO administration to Swiss mice in­
fected with P. vinckei petteri. DFO was 
either injected i.p. at the indicated dose, 
starting 2 days postinfection at a fre­
quency of three times/day for 3 days or 
administered as a 40% drug- polymeric 
s.c. implant. Each line represents the 
percent parasitemia of a single mouse. 
D = death.
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and determining the amount released into the PBS by UV absorption 
at 333 nm .
The matrices containing given amounts of drug were implanted 
s.c. or i,p in infected mice. The devices were dipped in 70% ethanol 
for sterilization and inserted through an incision in the lower ab­
dominal region of ether-anesthetized mice. The implanted devices 
were retrieved from the implant site of some of the treated animals, 
and the drug content was quantified to determine total drug release 
(Domb, 1994).
Experimental Design
Chelators were either injected at a frequency of three times a day 
for 2 or 3 consecutive days, or administered as polymeric devices on 
day 2, 3 or 4 after infection. Each experiment was performed at least
three times (usually with 5 -6  mice/group). Statistical analysis was 
conducted for each individual experiment. This approach was 
adapted because of variability between results obtained in different 
experiments caused by variations inherent in the biological systems. 
These include mice and experimental factors, such as the stage in the 
life cycle of the plasmodia in the infective inoculum, However, all 
individual experiments lead to the same qualitative conclusions. 
Consequently, we depicted a graphically representative set of results 
for each type of experiment and conducted statistical evaluation of 
two parameters; the parasitemia 2 days after drug administration 
(decreased values indicate a delay in parasite development) and the 
highest value of parasitemia (peak parasitemia). Significance is de­
fined in terms of a(2), the two paired probability according to Mann- 
Whitneys’ test (with values above .05 indicating no statistically 
significant difference between experimental and control groups).
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Fig. 3. Comparative efficacy of modes 
of SIH administration to Swiss mice in­
fected with P. vinckei petteri. SIH was 
either injected i.p. at the indicated dose, 
starting 2 days postinfection at a fre­
quency of three times/day for 2 days or 
administered as a 40% drug- polymeric 
s.c. implant. Each line represents the 
percent parasitemia of a single mouse, 
D -  death.
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Mice that recovered from malaria were followed for an additional 
month to monitor possible recurrence of parasitemia. In some exper­
iments, mice were challenged after this period with viable plasmodia 
to assess the acquisition of immunity,
Results
I n  v itro  release of DFO and  SIH. The iron chelators 
used for these studies were selected on the basis of their 
performance as growth inhibitors in in vitro cultures 
(Tsafack et al., 1996b). A series of preliminary experiments 
were conducted to evaluate the in vitro release of the iron 
chelators from drug-loaded polymers of poly(FAD-SA). The 
two factors considered were drug dose and the weight ratio of 
drug/polymer which determine the rate of drug release. The 
higher the ratio of the hydrophilic drug to the polymer, the
faster the release of drug, and vice versa, for lipophilic drugs 
(Domb, 1994). Different doses of drug were obtained by 
weighing a given preparation of the drug-containing poly­
mer. Figure 1 displays the cumulative drug-release profiles 
for various drug/polymer formulations. Although a 30% DFO- 
containing polymer (wt/wt) released the 70-mg dose contin­
uously during a 7-day period, a 40% polymer containing the 
same DFO dose released the drug at about 25% faster speed 
during the first 2 days (fig. 1A). We selected the 40% poly­
mers for all the reported studies with animals. The release of 
the lipophilic SIH from 40% polymers was linear for the first
3 days for the various doses used (5-50 mg). In a 6-day 
period, 65 to 95% of the drug was released from the polymers 
which were selected for further experiments (above 20 mg, 
fig. IB). The experiments were performed in triplicates and
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repeated at least three times. For each individual experiment 
the standard deviation exceeded no more than 10% of the 
mean value.
In vivo effects of DFO. The effects of DFO on an animal 
model of malaria were assessed in relation to the mode of 
administration: i.p. injections of DFO (fig. 2A) and s.c. or i.p. 
implants of the polymer containing DFO (fig. 2B). Swiss mice 
infected with P. vinckei petteri (3 X  106 parasitized erythro­
cytes) by i.p. injection of infected blood were treated starting 
from day 2 postinfection, at which point the first parasites 
were detected in peripheral blood (parasitemia = 0.01%, 
herewith defined as onset of patency). The treatment com­
prised either i.p. injections of DFO (2.5- or 5-mg DFO doses in 
50 jui saline, three times per day for 3 days) or a single s.c. 
insertion of the drug-containing device. Analysis of a dose- 
response profile of the injected DFO revealed that although
2.5 mg doses were ineffective, 5-mg doses led to marked 
reduction in parasitemias and total elimination of mortality. 
A peculiar feature displayed by some animals treated with
2.5 mg DFO was an unexplained death at 3 to 5 days after 
cessation of treatment and after a demonstrable clearance of 
parasites from the peripheral blood (fig. 2A), The s.c. inser­
tion of a single polymeric tablet containing 70 or 140 mg DFO 
also conferred protection to infected mice (fig. 2B). This was 
manifested as a reduction in parasitemia, a delay in peak 
parasitemia and a reduction in mortality. After peak para­
sitemia, there was an abrupt clearance of parasites in DFO- 
treated animals, as manifested by the parasitemias. The 
presence of the polymer, with or without drug, was appar­
ently well tolerated by the mice and there were no indications 
of adverse reactions or toxicity. The antimalarial effect of the 
DFO tablet was essentially identical whether the polymer 
was inserted s.c. or i.p. (data not shown).
In vivo effects of SIH. A dose-response effect was ob­
tained after SIH i.p injections three times per day for only 2 
days. Additional i.p. injections of SIH were generally avoided, 
particularly with relatively high doses of drug, because of 
toxic and« occasional lethal effects of prolonged treatments. 
Although 2-mg SIH injections (in DMSO, 50 /xl) had virtually 
no effect on the course of the infection, 4-mg injections (in 
DMSO, 50 /xl) produced a fast attenuation of the infection 
and prevented death in most of the animals (fig. 3A). It 
should be noted that although SIH was initially dissolved in 
DMSO for injection into animals, the SIH-containing poly­
mer was rendered mostly free of DMSO. A result analogous 
to that produced by DFO was obtained with polymeric inserts 
of SIH. The drug released from a single 35-mg SIH-polymer 
insert significantly delayed the parasite infection, and most 
of the animals survived at a dose of 65 mg (fig. 3B). The data 
shown in figures 2 and 3 revealed similar performances of 
DFO and SIH. This includes also an abrupt decrease in 
parasite survival after reaching peak parasitemia values. 
However, a closer inspection of the data obtained during the 
first 2 days of treatment which started at patency (when 
parasitemia was about 0.01%) reveals a marked difference in 
the onset of inhibition of parasite proliferation by both drugs 
(table 1). The treatment, which commenced 2 days after 
infection, included multiple injections of either SIH ( 3 X 2  
mg/mouse/day) or DFO (3 X  2.5 mg/mouse/day) or implants 
of SIH (35 mg) or DFO (70 mg). Although the dose of SIH was 
relatively lower or equal to that of DFO, at day 3 of infection
(day 1 of treatment), the inhibition of parasite proliferation 
was already 60% and 72% for SIH administered by injection 
and by polymer implants, respectively, whereas for DFO the 
values were 15 and 29%, respectively. At day 4, SIH was still 
more effective than DFO when given by injection, but equally 
effective when given by polymer. It should be stressed that 
the speed of action of SIH was faster despite the fact that it 
was used at relatively lower iron-chelating doses than DFO, 
because DFO binds iron at 1:1 stoichiometry whereas SIH 
binds it at 2:1 stoichiometry (Baker et al., 1992).
To further assess the efficacy of the antimalarial treatment 
in controlling progression of the disease, we examined the 
polymer-drug implants on animals that had reached fulmi­
nant stages of infection, that is at 1% and 9.5% parasitemia. 
The results shown in figure 4 indicate that both DFO (70 mg) 
and SIH (35 mg) were demonstrably effective in attenuating 
parasite proliferation and reducing mortality of infected an­
imals even at a late stage of the infection. At the relatively 
lower dose (35 mg SIH vs. 70 mg DFO), SIH gave better 
protection than DFO, particularly when applied at high 
(9.5%) parasitemia. However, it should be emphasized that 
the two agents could not be assessed at the same concentra­
tion, either because DFO was inefficient at doses <50 mg/ 
implant, or because of SIH apparent toxicity at doses >50 
mg/implant*
Combined in vivo  action of DFO and SIH. A combina­
tion of DFO and SIH added in separate polymers was exam­
ined and compared with the individual effects of the two 
drugs. A 50-mg DFO dose had only a minor effect on the 
course of infection, whereas a 20-mg SIH dose significantly 
attenuated it and reduced mortality. However, the combina­
tion of the two drugs had a more pronounced effect, particu­
larly in preventing mortality (fig. 5).
Effect of DFO on a rodent model of CM. The effect of a 
DFO-containing polymer was also examined on C57BI mice 
infected with P. berghei k l73 . The treatment commenced at 
day 6 postinfection, when parasitemias reached about 1%. 
Preliminary studies indicated that administration of DFO by 
injection (up to 12 mg X  3/day/5 days) was ineffective in 
changing the course of the disease (not shown). However,
TABLE 1
The effects of DFO and SIH on in vivo parasite development at 
the initial stages of treatment
Mice infected with P. vinckei petteri (five mice per group) were treated with either 
DFO or SIH starting at day 2 postinfection (P — 0.01 %) as follows: DFO injections 
were given i.p. in saline at a dose of 2.5 mg/mouse for 3 days, three times daily 
(8 h apart) (control = saline only). SIH Injections were given in DMSO for 2 days 
(2 mg/mouse, same regimen as DFO) (control -  DMSO only). Polymers (40%) 
containing either 70 mg DFO or 35 mg SIH were implanted s.c. on day 2 
postinfection. Each group of "treatment consisted of 10 infected mice, 5 control 
and 5 treated. P =  average % parasitemias (S.E. values were <10%). The 
inhibition of growth was significantly higher [P <  .05) for SIH- relative to DFO- 
treated mice on day 3 (both by injection and by polymer implant: 72% vs. 29% 
and 60% vs. 15%, respectively) and on day 4 (only by injection: 73% vs. 14%).
Drug Treatment of Parasitemia
i.p. injection Polymer implantation
day 3 day 4 day 3 day 4
Control P 4.8 20 2.1 9.1
DFO P 4.1 17 1.5 1.1
% inhibition 15 14 29 87
Control P 5.3 17.5 1.5 8.9
SIH P 2.2 4.8 0.4 0.9
% inhibition 60 73 72 91
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animals treated with s.c. inserts of polymers containing 140 
mg DFO had a significant reduction in parasitemia and relief 
from CM symptoms (table 2).
Recurrence of parasitem ias in  polymer-treated 
mice. Mice which recovered after treatment (about 2 weeks 
after infection, figs. 2-5) were observed for an additional 
month to monitor possible recurrence of disease. Blood smear 
examinations (twice a week) revealed no parasites. These 
mice were challenged after this period with 20 X 106 para­
sitized erythrocytes and did not show any parasitemias over 
a further 2 weeks» This experiment was repeated twice with 
mice from all the experimental groups, including convales­
cent mice from control groups. Typical high parasitemias and 
mortality were demonstrated in control mice which had not 
been previously exposed to malaria.
Discussion
The demand for new chemotherapeutic strategies for the 
treatment of malaria has increased with the widening spread 
of parasite drug resistance. This is demonstrated in the case 
of mefloquine, which is widely used for the treatment of 
malaria and is the prophylactic drug of choice (Wallace et a l, 
1996). Strategies to overcome resistance have relied on the 
application of single or pairs of drugs of either different 
chemical character and mode of action (Vennerstrom et a l }
1991) or similar mode of action but different cytotoxicity for 
the various stages of parasite growth. The latter strategy was 
used primarily with iron chelators in combination with DFO 
(Golenser et aL> 1995; Tsafack et a l ,  1995; Cabantchik et ali 
1996), a clinically approved agent that can only be given
1997 Polymeric Chelators and Malaria 1133
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parenterally, thus demanding hospitalization. Oral chelators 
of the hydroxypyridinone family, which are highly efficient in 
the treatment of iron overload (Olivieri et al., 1995), were 
virtually ineffective in human clinical trials of malaria (Ma- 
beza et a l } 1996), despite the fact that some of them showed 
antimalarial activity in infected mice (Hershko et a l ,  1991).
For animal chemotherapy of malaria based on iron chela­
tors, we considered four factors which might affect the effi­
cacy of thê treatment: 1) the proven in vitro record of the 
such as speed of action and wide action profiles on all 
blood stages of parasite development; 2) the possibility of 
parenteral drug treatment based on a single drug applica­
tion; 3) the possibility of attaining sustained blood levels of 
the drug by slow-drug release devices; and 4) possible syner­
gistic effects of combination of drugs. The most effective 
antimalarial iron chelators we have tested in vitro were 
reversed siderophores of high lipophilic character (Lytton et 
al.y 1994), particularly when used in combination with the 
hydrophilic DFO (Golenser et a l 1995; Tsafack et aL, 1996b). 
However, the poor aqueous solubility of lipophilic agents 
limited their animal usefulness because of the need for re­
peated injections and the mode of action of both types of 
agents which demanded extended exposure of the parasites. 
Both limitations could be overcome by use of polymers as 
possible carriers of lipophilic and hydrophilic drugs and as 
slow drug release devices.
The polymers we considered were (Domb, 1994; Domb et 
al., 1995): 1) biodegradable, whose products are eliminated 
from the organism; 2) implantable as drug carriers (e.g., 
polysilicones, ethylene-vinyl acetate copolymers, various ac- 
rylate-based hydrogels and segmented polyurethane) or as 
cleavable drug-polymer conjugates; 3) nontoxic, both locally 
and systemically. Other considerations given were drug load­
ing and uniformity, duration and rate of drug release, phar­
macokinetics of polymer degradation products, route of ad­
ministration, drug stability in the polymer, storage stability 
and a possibility of terminal sterilization (by 7-irradiation). 
The selected polymers used were composed of sebacic acid 
and a dimer of erucic acid, linked by hydrolyzable anhydride 
bonds. They were produced as s.c. or i.p. implantable tablets, 
although they can be formulated as injectable microspheres 
or small pellet inserts (Domb and Maniar, 1993). The test
TABLE 2
Effect of DFO~potymer implants on parasitemia and CM symptoms in a rodent CM model of malaria
Day refers to time after infection (treatment was initiated on day 6: a s.c. implant of DFO (140 mg drug, 40% polymer). P =  percent parasitemia; T =  body temperature; 
S = mice survival; ND =  not determined.
Day 8 Day 9 Day 10
}
S P T S P T
* «
« j
Day
11
34 31.2 11/11 36 27.0 8/11 ND 27.7 2/11 0/11
DFO 7 35.4 5/5 5 31.7 4/5 ND 36.6 3/5 3/5
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TABLES 3-6
Statistical analysis of results from Figs. 2 to 5, respectively.
Treatment Parasitemia at Day 4 Peak Parasitemia
Control 22.4 ± 1.5 68.0 ± 3.0
9 X 2.5 mg 16.9 ± 3.3 a(2) = 0.1 65.0 ± 3.5 a{2) >  0.2
DFO
9 X 5 mg 3.3 ± 1.9 «(2) = 0.01 14.6 ± 5.9 a(2) = 0.01
DFO
Control 9.1 ± 2.1 63.2 ± 8.8
70 mg DFO 1.1 ±0 .2  a(2) = 0.02 66.2 ± 3.9 a(2) >  0.2
140 mg 0.3 ± 0.1 a(2) = 0.005 32.8 ±11.3 a(2) ^  0.2
DFO
TABLE 4
Treatment Parasitemia at Day 4 Peak Parasitemia
Control 16.8 ± 2.6 72.6 ± 1.4
6 X 2 mg SIH 5.5 1.1 a( 2) == 0.005 74.1 ± 1.3 a(2) >  0.2
6 X 4 mg SIH 0.3 0.11 a(2) == 0.02 58.5 ± 6.7 «(2) = 0.1
Control 5.8 ± 1.1 62.4 ± 2.1
35 mg SIH 0.3 H- 0.1 a(2) == 0.002 52.8 ±4.7 «(2) = 0.2
65 mg SIH 0.1 ± 0.1 «(2) =: 0.002 54.0 ±4.8 a(2) >  0.2
TABLE 5
Treatment Parasitemia at Day 5 Peak Parasitemia
Control 
35 mg SIH 
70 mg 
DFO
Control 
35 mg SIH 
70 mg 
DFO
17.3 ± 1.2 
6.0 ± 0.4 a{2) = 0.002
3.4 ± 0.3 a(2) = 0.002
Parasitemia at day 6 
59.9 ± 2.4
2.5 ± 0.5 a(2) = 0.002 
45.4 ± 6.0 a(2) = 0.05
63.1 ± 3.0
43.6 ± 2.9 a(2) « 0.002
46.8 ± 5.7 a{2) = 0.03
64.3 ± 2.0
31.6 ±4 .6  a(2) = 0.002
48.8 ±  5.3 a(2) =  0.075
TABLE 6
Treatment Parasitemia at Day 4 Peak Parasitemia
Control 
20 mg SIH 
50 mg DFO 
20 mg SIH
10.6 ± 1.1 
0.1 ± 0.01 ol(2) =  0.035 
5.2 ± 1.6 a(2) = 0.035 
0.1 ± 0.01 a(2) =  0.005
59.8 ± 4.1 
47.1 ± 7.5 a(2) « 0.2 
65.6 ± 3.4 a (2) & 0.2 
41.5 ± 9.1 a{2) = 0.1
DFO
iron chelators selected for this study were the lipophilic SIH 
and the hydrophilic DFO. The results indicated that the 
drug-containing tablets fulfilled the above-stated require­
ments in terms of sterility, lack of toxicity and slow-release 
properties, which were apparently dictated by the relative 
amount of drug in the polymer (Domb, 1994). With the hy­
drophilic DFO, the higher its relative content in the polymer, 
the higher the overall hydrophilicity of the device and the 
speed of drug release (fig. 1A). The converse was apparently 
the case with the lipophilic SIH, as shown in figure IB.
In tests performed in Swiss mice infected with P. vinckei 
petteri, the polymers containing 70 mg DFO or 65 mg SIH 
gave results similar to those of three i.p. injections/day/3 
days of 5 mg DFO (a total of 45 mg DFO) or three injections/ 
day/2 days of 4 mg SIH (a total of 24 mg SIH) (figs. 2 and 3). 
These were manifested in delay of peak parasitemia and 
lower mortality. Although at comparable polymeric doses, 
SIH outperformed DFO in terms of speed of action (table 1), 
the overall performance of both drugs in reducing parasite
load and mortality was similar (figs. 2 and 3). Both SIH and 
DFO polymer insertions were effective even when the initial 
parasitemias were as high as 9.5% (fig. 4). Combinations of 
the iron chelators should be considered because they were 
more efficient than the individual polymers in reducing mor­
tality (fig. 5).
The effect of slow release of iron chelators was also exam­
ined on a CM model in mice infected with P. berghei highly 
resistant to DFO. Six days postinfection, when parasitemias 
were about 1%, the animals were treated by s.c. insertion of 
tablets containing 140 mg DFO. The treatments reduced 
parasitemias and also prevented CM symptoms in most of 
the mice, whereas repeated injections of DFO were ineffec­
tive in this model.
The rapid clearance of parasites from chelator-treated an­
imals that have reached relatively high parasitemia might be 
indicative of an improved clearance of parasites by the re­
ticuloendothelial system. Such action might be the result of 
chelator- mediated reduction of toxic iron load which is gen­
erated by phagocytosis of infected cells and which might 
hamper macrophage activities (Schwarzer et aL, 1992). Thus, 
this mode of chelator action should be added to the proposed 
modes of action of iron chelators as antimalarial s. These have 
been focused either on chelator action on intraerythrocytic 
parasites (reviewed in Gordeuk, 1994; Cabantchik 1994; Ca­
bantchik et aL, 1996) or in the prevention of pathological 
iron-dependent processes (Hunt et al., 1992; Golenser and 
Chevion, 1994; Mabeza et al., 1996). Drug treatment may 
affect the course of the disease directly by killing the plas­
modia and indirectly by altering the immune responses (e.g., 
by changing cytokine response). Recent retrospective clinical 
studies support the notion of a possible iron chelator action 
on immune cell responses (Thuma et a l 1996). This also 
strengthens the suggestion that chemotherapy should be 
complementary to vaccination (Tanner and Evans, 1994).
Taking in toto the results of this study and the clinical 
record of DFO (Gordeuk et aL, 1994; Mabeza et al., 1996), we 
propose that iron chelators delivered by slow-release poly­
meric devices can be advantageous for malaria therapy. They 
can be particularly useful when used as combinations of 
drugs that display different speeds of action. Moreover, sim­
ilar parenteral treatments might be also applicable to iron- 
overloaded individuals that require frequent iron chelation 
therapy (Olivieri et al.t 1995; Porter, 1996).
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